We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
-10.45%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$135M
AUM Growth
-$151M
(-53%)
Cap. Flow
-$109M
Cap. Flow
% of AUM
-80.48%
Top 10 Holdings %
Top 10 Hldgs %
67.63%
Holding
31
New
1
Increased
3
Reduced
16
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$4.96M |
| 2 |
Guardant Health
GH
|
+$3.76M |
| 3 |
Rapid Micro Biosystems
RPID
|
+$1.93M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$1.48M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Natera
NTRA
|
+$25M |
| 2 |
Repligen
RGEN
|
+$18.5M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$12.5M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$10.8M |
| 5 |
IDEAYA Biosciences
IDYA
|
+$10.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Lantheus
LNTH
$7B
| $15.8M | 11.68% |
285,000
-45,000
| -14% | -$1.69M |
|
|
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $10.9M | 8.11% |
650,000
+100,000
| +18% | +$1.48M |
|
|
3
Guardant Health
GH
$20.7B
| $10.6M | 7.86% |
160,000
+55,000
| +52% | +$3.76M |
|
4
Arvinas
ARVN
$517M
| $10.1M | 7.48% |
150,000
-80,000
| -35% | -$5.45M |
|
5
Cogent Biosciences
COGT
$6.68B
| $9.81M | 7.27% |
1,309,430
-192,161
| -13% | -$1.34M |
|
6
Viridian Therapeutics
VRDN
$1.99B
| $9.17M | 6.8% |
496,012
-108,762
| -18% | -$2.09M |
|
7
Fate Therapeutics
FATE
$324M
| $7.04M | 5.22% |
181,500
-88,500
| -33% | -$3.43M |
|
8
Nuvation Bio
NUVB
$2.02B
| $5.98M | 4.43% |
1,137,152
-60,000
| -5% | -$337K |
|
|
CERE
9
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $5.95M | 4.41% |
+170,000
| New | +$4.96M |
|
|
SLGC
10
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $5.89M | 4.37% |
735,000
-65,000
| -8% | -$573K |
|
|
ISO
11
DELISTED
IsoPlexis Corporation Common Stock
ISO
| $5.66M | 4.2% |
1,650,118
-120,000
| -7% | -$695K |
|
|
12
Rapid Micro Biosystems
RPID
$103M
| $4.75M | 3.52% |
699,664
+261,704
| +60% | +$1.93M |
|
13
Nautilus Biotechnolgy
NAUT
$221M
| $4.69M | 3.48% |
1,080,566
-144,494
| -12% | -$593K |
|
14
Intellia Therapeutics
NTLA
$1.59B
| $4.36M | 3.23% |
60,000
-5,000
| -8% | -$424K |
|
|
SYRS
15
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $4M | 2.97% |
336,490
-17,500
| -5% | -$313K |
|
16
Gossamer Bio
GOSS
$83.2M
| $3.91M | 2.9% |
450,000
-25,000
| -5% | -$241K |
|
|
JNCE
17
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $3.73M | 2.77% |
550,000
-25,000
| -4% | -$178K |
|
18
Stoke Therapeutics
STOK
$1.81B
| $3.68M | 2.73% |
175,000
-10,000
| -5% | -$200K |
|
19
Sight Sciences
SGHT
$274M
| $3.64M | 2.7% |
314,804
-27,500
| -8% | -$423K |
|
|
MDVL
20
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| $2.84M | 2.1% |
58,416
| – | – |
|
|
VERV
21
DELISTED
Verve Therapeutics
VERV
| $2.4M | 1.78% |
105,360
-5,000
| -5% | -$143K |
|
|
22
IDEAYA Biosciences
IDYA
$3.47B
| – | – |
-430,000
| Closed | -$10.2M |
|
23
Iovance Biotherapeutics
IOVA
$2.23B
| – | – |
-406,986
| Closed | -$7.77M |
|
|
CYPH
24
Cypherpunk Technologies Inc
CYPH
$75.4M
| – | – |
-181,500
| Closed | -$5.88M |
|
25
MacroGenics
MGNX
$285M
| – | – |
-30,000
| Closed | -$482K |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q1 2022 Portfolio in Review
As of Q1 2022, Ally Bridge Group held 31 positions worth $135M, down 53% from $286M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Ally Bridge Group withdrew a net $109M in Q1 2022, closing 10 positions and reducing 16 holdings. Its most notable exit was Natera, an estimated $25M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.
Against the trend, Ally Bridge Group opened a new position in Cerevel Therapeutics Holdings, Inc. Common Stock worth $5.95M.
- Ally Bridge Group's largest Q1 2022 buy was Cerevel Therapeutics Holdings, Inc. Common Stock: 170,000 shares worth $5.95M.
- Ally Bridge Group added most to Guardant Health in Q1 2022, an estimated $3.76M increase.
- Ally Bridge Group's biggest Q1 2022 reduction was Arvinas, cutting an estimated $5.45M.
- Ally Bridge Group fully exited Natera in Q1 2022, selling an estimated $25M.
- Ally Bridge Group's ten largest holdings make up 68% of its $135M portfolio in Q1 2022.
- Ally Bridge Group opened 1 new position and closed 10 in Q1 2022.
- Ally Bridge Group's portfolio value fell 53% quarter-over-quarter to $135M.
Based on Ally Bridge Group's 13F filing for Q1 2022, filed 16 May 2022.